Simona Pisegna | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study	THE ONCOLOGIST	2024
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2024
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z)	NPJ BREAST CANCER	2024
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2023
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma	CANCERS	2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey	TUMORI	2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study	FRONTIERS IN ONCOLOGY	2023
The Strange Case of a Pancreatic Neuroendocrine Carcinoma with Low Proliferation Index and Atypical Clinical Behavior	PANCREAS	2022
127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma	ANNALS OF ONCOLOGY	2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy	FRONTIERS IN IMMUNOLOGY	2022
Role of chemotherapy in vulvar cancers: time to rethink standard of care?	CANCERS	2021
Comparison of two blood-based genotyping tests to investigate the KRAS G12C mutation in patients with non-small-cell lung cancer at failure of first-line treatments	DIAGNOSTICS	2021
3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors	ANNALS OF ONCOLOGY	2021
Tissue immune profile: a tool to predict response to neoadjuvant therapy in triple negative breast cancer	CANCERS	2020
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer	LUNG CANCER MANAGEMENT	2020
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence	ANNALS OF ONCOLOGY	2017